The company provides an end-to-end, global cloud platform with a flexible suite of tools that allows sponsors, patients, providers & CROs to work together as a team in clinical trials.
The company’s vision is to accelerate the path to human discovery and medical cures.
Colin Weller, vice president and general manager of Evidence Platform, he agreed to answer some questions ahead of the event.
Why do you think it is important to attend SCOPE?
SCOPE is renowned for its focus on the latest innovations across clinical operations and trials. Whether it’s technology or emerging best practices, attendees gain first-hand insights from experts at the forefront of the industry. This knowledge is not just theoretical but often comes with practical advice and case studies, making it immediately applicable. The ‘how’ of delivering clinical trials in innovative ways to achieve significant value such as ‘speed to decision point’ often plays second fiddle to the core scientific principles of a clinical trial but at scope, operational excellence is primary.
What do you hope to achieve this year while you are there?
I hope to renew old and make new connections to drive further collaboration with colleagues who share the same goal of bringing medicines to patients faster. In my podium presentation, I also hope to shine a light on the progress that is being made in driving down the stubborn 12-year drug development lifecycle.
Do you have an inkling what the buzz theme will be this year?
Considering the rapid advancements in AI, it’s likely that this year’s buzz theme could center on the integration of AI or intelligent automation in evidence generation. Given AI’s advancements, discussions could revolve around how AI is streamlining data collection, enhancing patient engagement strategies, improving trial design and delivery, and ensuring better data integrity. The integration of AI in these areas not only promises to increase the efficiency and effectiveness of clinical trials but also poses questions about regulatory challenges and ethical considerations in this rapidly evolving field.
For those who have never attended SCOPE before, what would you say to entice them?
One of the most significant advantages of attending SCOPE is the unparalleled networking opportunities. It’s a melting pot of leaders, innovators, and peers across the clinical trial industry. Plus, it’s an opportunity to learn about the latest trends and best practices.
What part of it are you looking forward to the most?
Selfishly, I am looking forward to presenting Medable’s insights on ‘The New Frontier: How Intelligent Automation is Transforming Clinical Deployment.’ This topic is generating a lot of interest among our customers, and we’re thrilled to have the opportunity to share with the wider industry. We’ll be showcasing our intelligent automation innovation and the latest results, including a 50% reduction in trial technology deployment timelines.
